Is the nephrology community facilitating excess cardiovascular
deaths in patients with kidney failure and anemia by treating to a
subnormal hematocrit? Why have clinicians and nephrologists
permitted health insurance companies and the government to decide
when anemia therapy should begin in persons with progressive kidney
failure? Is iron the only variable that can be manipulated to
maximize response to recombinant erythropoietin? Are we using too
much intravenous iron in kidney failure patients, and is oral iron
supplementation worthless in sustaining iron stores during
long-term erythropoietin treatment? When does left ventricular
hypertrophy begin to emerge in patients with progressive renal
disease and is there convincing evidence that anemia is a
significant cause of LVH in this setting? Is darbepoetin alfa, a
new novel, long-acting erythropoietin, really superior to
recombinant erythropoietin? This book is a compilation of
proceedings from a conference in Brooklyn convened to address these
and other controversial and unresolved issues in renal anemia
management.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
